logo-loader
viewRedx Pharma PLC

Redx Pharma's Lisa Anson discusses potential US$203mln cancer deal

Redx Pharma PLC's (LON:REDX) Lisa Anson speaks to Proactive London's Andrew Scott after announcing they've sold one of their cancer research programmes for up to US$203mln.

The agreement with Jazz Pharmaceuticals (NASDAQ:JAZZ) has a tiered payment structure and will see Redx receive a upfront sum of US$3.5mln.

Quick facts: Redx Pharma PLC

Price: 31 GBX

AIM:REDX
Market: AIM
Market Cap: £58.9 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma 'on a firm footing and able to drive its business plan'...

Redx Pharma PLC's (LON:REDX) Lisa Anson caught up with Proactive London's Andrew Scott after announcing they've raised US$30mln via the issue of convertible loan notes. Funds Redmile Group and Sofinnova Partners are putting up US$19mln and US$10mln respectively. The cash will be used to...

1 week, 6 days ago

2 min read